Jubilant Pharmova peers

·Pharma & HealthChart ›

Companies like Jubilant Pharmovalatest year

Jubilant PharmovaJUBLPHARMA · FY26 · this company
Market cap₹14,914
P/E37.53×
Sales growth+17.3%
ROE6.0%
Gland PharmaGLAND · FY26
Open ›
Market cap₹50,235
P/E48.90×
Sales growth+19.6%
ROE10.5%
Piramal PharmaPPLPHARMA · FY26
Open ›
Market cap₹30,896
P/E—
Sales growth+28.1%
ROE−4.0%
Krishna Institute of Medical SciencesKIMS · FY26
Open ›
Market cap₹28,184
P/E116.85×
Sales growth+35.3%
ROE11.0%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JUBLPHARMA₹943.90

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹14,914 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
JUBLPHARMA
FY26
GLAND
FY26
PPLPHARMA
FY26
KIMS
FY26
Peer
Average
Valuation — at last close
P/E◆ 37.53×48.90×—116.85×82.88× -55%
P/B◆ 2.10×4.85×3.79×12.54×7.06× -70%
EV/EBITDA◆ 13.39×28.92×38.02×39.46×35.46× -62%
Market Cap₹14,914 Cr₹50,235 Cr₹30,896 Cr₹28,184 Cr₹36,439 Cr -59%
Growth
Revenue CAGR 3Y9.64%21.06%7.79%◆ 21.12%16.66% -42%
Revenue CAGR 5Y6.31%13.18%—◆ 24.04%18.61% -66%
Net Income CAGR 3Y—◆ 9.57%—-12.87%-1.65%
Revenue YoY (latest Q)17.29%19.57%28.05%◆ 35.33%27.65% -37%
Net Income YoY (latest Q)-44.98%47.09%◆ 105.07%-56.00%32.05% -240%
Profitability
EBITDA Margin15.22%◆ 25.34%10.39%20.54%18.76% -19%
Net Income Margin4.80%◆ 15.98%-3.68%6.20%6.17% -22%
Return on Common Equity5.97%10.53%-4.00%◆ 11.01%5.85% +2%
Return on Capital Employed6.95%◆ 11.73%0.72%9.09%7.18% -3%
Return on Assets2.81%◆ 8.66%-1.94%3.59%3.44% -18%
Credit & Quality
Total Debt/Equity0.45×◆ 0.02×0.67×1.27×0.65× -31%
Interest Coverage3.87×◆ 36.24×0.27×2.56×13.02× -70%
Scale — latest FY
Revenue / Total Income₹8,280 Cr₹6,431 Cr₹8,869 Cr₹3,905 Cr₹6,401 Cr +29%
Net Income₹398 Cr₹1,027 Cr−₹326 Cr₹242 Cr₹314 Cr +26%
Total Assets₹15,523 Cr₹12,511 Cr₹17,965 Cr₹7,759 Cr₹12,745 Cr +22%
EPS₹25.15₹62.35₹-2.46₹6.03₹21.97 +14%
Book Value per Share₹448.91₹628.67₹61.5₹56.19₹248.79 +80%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.